Literature DB >> 16705502

[Povidone-iodine for treatment of adenoviral conjunctivitis: an in vitro study].

N Monnerat1, W Bossart, M A Thiel.   

Abstract

BACKGROUND: Adenoviral conjunctivitis causes high socioeconomic costs due to high contagiousness and therefore the need for extended quarantine. To date the only potentially active, topical antiviral agent is povidone-iodine (PVI). The aim of this study was to investigate the effect of diluted PVI on free adenovirus and adenoviral infected cells as well as to evaluate the cellular toxicity of PVI on non-infected cells.
MATERIAL AND METHODS: PVI was diluted to a final concentration of 0.0008 %. Virucidal activity was measured IN VITRO using adenovirus 8 and A549 human epithelial cell cultures. Cytotoxicity effects on healthy cells after short- and long-term exposure to diluted PVI were measured in A549 cell cultures.
RESULTS: Exposure to PVI at a concentration of 1:10 (0.8 %) completely extinguishes infectivity of free adenovirus after an exposure time of 10 minutes. PVI is less effective against intracellular adenovirus resulting in a decreased infectivity and viral activity for approximately one day with a narrow spectrum between toxicity and virucidal activity. Healthy epithelial cells can be exposed to PVI for up to 6 hours without a cytotoxic effect.
CONCLUSIONS: PVI is highly effective against free adenovirus but less effective against intracellular adenoviral particles in already infected cell. Short- and long-term exposure of PVI causes little cytotoxicity for healthy cells. Therefore, administration of diluted PVI at a concentration of 1:10 is a potential option to reduce contagiousness in cases of adenoviral infections.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16705502     DOI: 10.1055/s-2006-926633

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  7 in total

Review 1.  Epidemic keratoconjunctivitis: the current situation and recommendations for prevention and treatment.

Authors:  Birthe Meyer-Rüsenberg; Ulrike Loderstädt; Gisbert Richard; Paul-Michael Kaulfers; Caroline Gesser
Journal:  Dtsch Arztebl Int       Date:  2011-07-08       Impact factor: 5.594

2.  The In Vitro Evaluation of Povidone-Iodine Against Multiple Ocular Adenoviral Types.

Authors:  Kathleen A Yates; Robert M Q Shanks; Regis P Kowalski; Eric G Romanowski
Journal:  J Ocul Pharmacol Ther       Date:  2018-12-27       Impact factor: 2.671

Review 3.  Treatment of viral conjunctivitis with antiviral drugs.

Authors:  Chrysanthi L Skevaki; Ioanna E Galani; Michail V Pararas; Konstantina P Giannopoulou; Athanassios Tsakris
Journal:  Drugs       Date:  2011-02-12       Impact factor: 9.546

Review 4.  Mystery eye: Human adenovirus and the enigma of epidemic keratoconjunctivitis.

Authors:  Rahul A Jonas; Lawson Ung; Jaya Rajaiya; James Chodosh
Journal:  Prog Retin Eye Res       Date:  2019-12-28       Impact factor: 21.198

5.  Efficacy and tolerability of polyvinylpyrrolidone-iodine 0.6% treatment in adenoviral keratoconjunctivitis: a Prospective Randomized Controlled Study.

Authors:  Gabriella Ricciardelli; Giuseppe Giannaccare; Antonio Di Zazzo; Marco Coassin; Vincenzo Scorcia; Mario R Romano; Davide Allegrini; Michela Cennamo; Marco Antonini; Federico Bernabei; Alberto Morelli; Rita Mencucci
Journal:  Eye (Lond)       Date:  2021-03-02       Impact factor: 3.775

6.  A treatment protocol for minimizing duration and complications of adenoviral epidemic keratoconjunctivitis.

Authors:  Chidanand Kulkarni; Kirthinath Ballal
Journal:  Taiwan J Ophthalmol       Date:  2019-10-24

7.  The in vitro Evaluation of the Activity of COVID-19 Antiviral Drugs Against Adenovirus.

Authors:  Eric G Romanowski; Kathleen A Yates; John E Romanowski; Robert M Q Shanks; Regis P Kowalski
Journal:  Clin Ophthalmol       Date:  2021-12-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.